A
Ambrx
A biopharmaceutical company with a mission to deliver breakthrough protein therapeutics
At a glance
- Founded
- 2003
- Headquarters
- San Diego, United States
- Listing
- IPO 2021
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
- MVM Ventures
Series B and later21 investors entered at this stage
- TGTavistock Group
- UCUniversity of California
- BEBerkeley
BlackRock- SGSinopharm Group
- ACAdage Capital
- ACApricot Capital
- RFRoche Venture Fund
Versant Ventures- CLChina Everbright Limited
- CCCMEA Capital
Cormorant Asset Management- 5V5AM Ventures
- NSNortheast Securities
- MCMaverick Capital
Fidelity Investments- INInvus
- ACApposite Capital
- AVAravis Ventures
- SMSuvretta Capital Management
- MIMaverick Ventures Israel
Source: Dealroom Talent Intelligence.
Alumni founders
Former Ambrx employees who went on to found companies, sorted by Dealroom signal score.
ARArdelyxEst. 2007
APAblaze PharmaceuticalsEst. 2021
Alan XuChina
ABAvidity BiosciencesEst. 2013
Troy WilsonUnited States
ETEffector TherapeuticsEst. 2012
Kevin EastwoodUnited StatesGlobal footprint
team presence
across markets
Patents
43 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ambrx on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ambrx on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.